Lv5
1230 积分 2022-09-06 加入
Obinutuzumab versus rituximab for the treatment of refractory primary membranous nephropathy
11天前
已完结
Comparison of obinutuzumab and rituximab for treating primary membranous nephropathy
11天前
已关闭
Obinutuzumab as Initial or Second-line Therapy in Patients With Primary Membranous Nephropathy
11天前
已完结
Comparison of obinutuzumab and rituximab for treating primary membranous nephropathy
25天前
已关闭
Obinutuzumab may be an effective and safe option for adult minimal change disease and focal segmental glomerulosclerosis patients after multitarget therapy including rituximab
29天前
已关闭
Obinutuzumab versus rituximab for the treatment of refractory primary membranous nephropathy
1个月前
已完结
Obinutuzumab may be an effective and safe option for adult minimal change disease and focal segmental glomerulosclerosis patients after multitarget therapy including rituximab
1个月前
已关闭
Lupus nephritis-related chronic kidney disease
1个月前
已完结
Anti-CD38 therapy for PLA2R-positive membranous nephropathy resistant to conventional immunosuppression
2个月前
已关闭
A case of treatment‐resistant membranous nephropathy associated with graft versus host disease successfully treated with daratumumab
2个月前
已完结
皖公网安备34019202002308
